Astrazeneca Pharma Poland sp. z o.o.

Other research and experimental development on natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-06-13
Share capital
2,000,000.00 PLN
Activity description

Astrazeneca Pharma Poland is a biopharmaceutical company that develops and manufactures medicines for major challenges in modern medicine. Its therapeutic areas include oncology, cardiovascular and metabolic diseases, respiratory diseases, autoimmune conditions, neurological diseases, infectious diseases and vaccines.

Registered address
ul. Postępu 14, 02-676 Warszawa, Poland
Email
Social media
Electronic delivery address
AE:PL-82425-23103-THBTS-19

Financials

Revenue history (in m)

Financial insight

  • The statement flags a going concern risk. N/A

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 52 days for 2023). All were audited by a statutory auditor.

  • 202526/06/2026
  • 202405/08/2025
  • 202305/09/2024
  • 202230/06/2023
  • 202127/07/2022
  • 202016/08/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top <1%
City · Warszawa151 / 56,729
Top <1%
Voivodeship · Mazowieckie177 / 76,892
Top <1%
Country · Poland410 / 297,069
Top <1%

Results vs industry

Revenue
This companyUSD 466.14mMedianUSD 73.13kAverageUSD 3.24m
Net profit
This companyUSD 53.48mMedianUSD 69.70AverageUSD 83.06k
Operating costs
This companyUSD 423.22mMedianUSD 75.83kAverageUSD 3.05m
Assets
This companyUSD 338.63mMedianUSD 120.25kAverageUSD 3.90m

Public procurement

4 tenders recorded as contractor, with a total value of $2,122,378.

SubjectAmount
Supplementary tender for the supply to WCSKJ of medicinal products used in drug programmes and chemotherapy
$1.6M
Purchase and supply of general hospital medicines for Samodzielny Publiczny Zakład Opieki Zdrowotnej w Puławach, divided into 83 lots.
$69,874
Supply of medicinal products from drug programmes and new medicinal products
$405K

Trademarks

The company currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2003.

MarkNumberClassesStatusProtected until
KLUB INTENSYWISTÓW WARSZAWSKICH Z.35764916, 41, 44Expired –
WOLNOŚĆ ODDECHU (word)Z.2655205, 10, 35, 36, 39, 41, 44Expired –
MarkProtected until
KLUB INTENSYWISTÓW WARSZAWSKICH –
WOLNOŚĆ ODDECHU (word)–

Authorized Representatives

Barbara Elżbieta Kozierkiewicz age 55 – Vice President of the Management Board
Edyta Wojtkiewicz age 52 – Vice President of the Management Board
Marta Paulina Jagnieża age 48 – Vice President of the Management Board
Wiktor Jerzy Janicki age 49 – President of the Management Board

Manner of representation

Each of the members of the management board is authorized to make declarations and sign documents on behalf of the company independently.

Ownership

OwnerSharesShare valueStake
Astrazeneca Continent B.v.
4,000$540,248.51100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2003-10-01.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 547.9K

Public aid

PurposeGross amount
Aid for research and development projects: experimental development
$1.7M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Adamed Pharma S.A.
Teva Operations Poland sp. z o.o.
Novartis Poland sp. z o.o.
Janssen-Cilag Polska sp. z o.o.
Bristol-Myers Squibb Polska sp. z o.o.
Takeda Pharma sp. z o.o.
Accord Healthcare Polska sp. z o.o.
Gilead Sciences Poland sp. z o.o.
Chiesi Poland sp. z o.o.
Solinea sp. z o.o.

Change history

DateEvent
2015-12-29Address change
2007-01-02Address change
2003-11-25Share capital increase
2003-10-09Address change
2002-08-19Address change

FAQ

Last updated: 2026-10-07